Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhelion Life SciencesFRA:4YX Receivables Turnover is 1.40 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 951 Drug Manufacturers companies, Rhelion Life Sciences ranks better than 78.86% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Rhelion Life Sciences's Revenue for the
three
months ended in Mar. 2026 was €0.55 Mil. Rhelion Life Sciences's average Accounts Receivable for the
three
months ended in Mar. 2026 was €0.39 Mil.
Hence, Rhelion Life Sciences's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.40.
Rhelion Life Sciences (FRA:4YX) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Rhelion Life Sciences Receivables Turnover Related Terms
Rhelion Life Sciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Rhelion Life Sciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhelion Life Sciences Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Rhelion Life Sciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhelion Life Sciences (FRA:4YX) has a Receivables Turnover of 1.40 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Rhelion Life Sciences and its competitors. According to the industry distribution chart, Rhelion Life Sciences ranks #201 out of 951 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is Rhelion Life Sciences' Receivables Turnover too high?
Rhelion Life Sciences' current Receivables Turnover is 1.40. The Drug Manufacturers industry median Receivables Turnover is 5.07. Rhelion Life Sciences' value of 1.40 is 72.4% below this industry median. Based on the distribution chart, Rhelion Life Sciences ranks #201 out of 951 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Rhelion Life Sciences' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Rhelion Life Sciences ranks #201 out of 951 companies for Receivables Turnover. This places Rhelion Life Sciences in the top 21% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Rhelion Life Sciences' value of 1.40 is 72.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhelion Life Sciences's current Receivables Turnover of 1.40 is 72.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Rhelion Life Sciences and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhelion Life Sciences's current Receivables Turnover is 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (FRA:4YX) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading 30% above its estimated fair value. The current Receivables Turnover is 1.40 and 72.4% below the Drug Manufacturers industry median of 5.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Rhelion Life Sciences (FRA:4YX), the current Receivables Turnover is 1.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4YX has been successfully added to your 
